GSA Capital Partners LLP Makes New $373,000 Investment in BioNTech SE (NASDAQ:BNTX)

GSA Capital Partners LLP acquired a new position in BioNTech SE (NASDAQ:BNTX) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 3,138 shares of the company’s stock, valued at approximately $373,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of BNTX. GAMMA Investing LLC grew its holdings in shares of BioNTech by 21.7% during the third quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock valued at $74,000 after buying an additional 111 shares during the last quarter. Covestor Ltd boosted its holdings in BioNTech by 47.2% in the first quarter. Covestor Ltd now owns 415 shares of the company’s stock worth $38,000 after purchasing an additional 133 shares during the last quarter. EverSource Wealth Advisors LLC boosted its holdings in BioNTech by 106.3% in the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock worth $43,000 after purchasing an additional 252 shares during the last quarter. Blue Trust Inc. boosted its holdings in BioNTech by 491.1% in the third quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after purchasing an additional 388 shares during the last quarter. Finally, Gallacher Capital Management LLC boosted its holdings in BioNTech by 12.1% in the second quarter. Gallacher Capital Management LLC now owns 3,657 shares of the company’s stock worth $294,000 after purchasing an additional 395 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Stock Performance

Shares of BNTX opened at $108.20 on Friday. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The firm has a market cap of $25.94 billion, a PE ratio of -51.52 and a beta of 0.26. The company’s 50 day simple moving average is $113.80 and its 200-day simple moving average is $97.56. BioNTech SE has a 12-month low of $76.53 and a 12-month high of $131.49.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, topping the consensus estimate of ($1.26) by $2.07. The company had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business’s revenue was up 38.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.73 EPS. As a group, equities analysts predict that BioNTech SE will post -3.68 EPS for the current year.

Analyst Upgrades and Downgrades

BNTX has been the topic of several recent research reports. Evercore ISI upgraded shares of BioNTech from an “in-line” rating to an “outperform” rating and increased their price target for the stock from $110.00 to $125.00 in a research report on Tuesday. The Goldman Sachs Group upgraded shares of BioNTech from a “neutral” rating to a “buy” rating and increased their price target for the stock from $90.00 to $137.00 in a research report on Friday, November 8th. Bank of America increased their price target on shares of BioNTech from $125.00 to $150.00 and gave the stock a “buy” rating in a research report on Monday, September 16th. Deutsche Bank Aktiengesellschaft increased their price target on shares of BioNTech from $95.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, September 19th. Finally, Jefferies Financial Group upgraded shares of BioNTech from a “hold” rating to a “buy” rating and increased their price target for the stock from $96.00 to $150.00 in a research report on Tuesday, September 17th. Four analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $138.79.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.